Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an announcement.
Neuren Pharmaceuticals announced that it will report its full-year 2024 financial results and host an investor webinar on February 28, 2025. The announcement follows the confirmation of the DAYBUE™ (trofinetide) royalty for Q4 2024, which will be included in the company’s audited financial statements. This development highlights Neuren’s ongoing efforts to strengthen its market position in the neurological drug therapy sector, with potential implications for stakeholders as the company continues to advance its drug candidates.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals is a company focused on developing new drug therapies for serious neurological disorders that emerge in early childhood, often with no or limited approved treatment options. The company has been granted ‘orphan drug’ designation in the United States, which provides incentives for developing therapies for rare and serious diseases. Their primary products include DAYBUE™ (trofinetide), approved for the treatment of Rett syndrome, and NNZ-2591, which is in development for multiple neurodevelopmental disorders.
YTD Price Performance: 12.63%
Average Trading Volume: 612
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.1B
See more data about NEU stock on TipRanks’ Stock Analysis page.